Quick Answer
Cartesian Therapeutics, Inc. reported Operating Income Loss of -$143.41 million for the year ending 2025.
- Cartesian Therapeutics, Inc. showed a decrease of -226.7% in Operating Income Loss from 2024 to 2025.
- This data is from Cartesian Therapeutics, Inc.'s annual report (Form 10-K), filed with the SEC on March 9, 2026.
- XBRL data for this metric is available from 2014 to 2025 (12 years of filings). Earlier data may not exist in machine-readable XBRL format as companies adopted electronic filing at different times.
- Over the full 12 years of available data (2014 to 2025), Cartesian Therapeutics, Inc.'s Operating Income Loss has declined by 831.3%.
- Historical annual values: Fiscal year 2025: -$143.41 million | Fiscal year 2024: -$43.90 million | Fiscal year 2023: -$86.42 million | Fiscal year 2022: $14.54 million | Fiscal year 2021: -$4.60 million | Fiscal year 2020: -$56.82 million | Fiscal year 2019: -$52.46 million | Fiscal year 2018: -$65.02 million | Fiscal year 2017: -$63.78 million | Fiscal year 2016: -$34.67 million | Fiscal year 2015: -$25.30 million | Fiscal year 2014: -$15.40 million.
- Data sourced from SEC EDGAR public filings as of June 21, 2026.
Last verified: